In a recent Reuters article, IPOX® VP Kat Liu, provided commentary on the upcoming IPO of property insurance technology company Slide. The company is reportedly targeting a valuation of up to $2.12 billion and aims to raise as much as $340 million.

In a recent report by Reuters, IPOX® Research Associate Dr. Lukas Muehlbauer provided commentary on the upcoming U.S. initial public offering of cancer diagnostic firm Caris Life Sciences. The company is aiming for a valuation of up to $5.3 billion, seeking to raise as much as $423.5 million.

In a Reuters report on Circle's successful market debut, IPOX® Research Associate Lukas Muehlbauer offered context on the strengthening IPO pipeline. He observed that the most successful recent listings have been from firms in resilient industries, stating they were "largely by companies less exposed to international supply chain risks" and that the trend would likely continue for sectors such as AI, defense, or fintech.

In a Reuters feature on Gemini's recent IPO filing, IPOX® Vice President Kat Liu commented on the growing trend of digital asset firms going public. Liu explained that this move signals a readiness from long-anticipated firms to re-engage with public capital. She noted, "investor appetite is returning, especially for companies with well-defined business models in strategic sectors such as fintech, AI and digital assets," highlighting the renewed market vigor for such offerings.

In a recent Bloomberg article, IPOX® Founder Josef Schuster provided his expert commentary on the U.S. IPO market's striking resilience despite recent volatility. He noted the market's ability to withstand bond market pressures, highlighting that strong performers like CoreWeave are boosting investor confidence. Schuster observed that "risk appetite is rising for certain deals," indicating potential for continued positive momentum given solid company fundamentals and performance.

In a recent Bloomberg article, IPOX® Founder Josef Schuster provided his expert commentary on Dubai's surging property market and its influence on REIT IPOs. He highlighted the expectation for REITs to "gain traction in the UAE as a separate tradeable asset class," given the strong investor interest. Schuster underscored the potential for international investors to diversify into the region with attractive yields, signaling a promising outlook for REIT IPO activity.

In a recent Bloomberg article, IPOX® Founder Josef Schuster provided his expert commentary on the evolving landscape for IPOs. He highlighted a significant shift towards a more favorable market environment with reduced risk, expressing optimism for upcoming insurance sector listings like Aspen and American Integrity. Schuster noted these IPOs are poised to perform well, signaling a potential revival in investor appetite.

IPOX® Analyst Lukas Muehlbauer provided context to Reuters regarding Aspen Insurance's planned IPO. Amid recessionary concerns, he noted continued investor interest is expected in defensive sectors less sensitive to economic headwinds or tariffs. Muehlbauer stated, "Insurance fits this profile," explaining the potential appeal of Aspen's return to the public markets currently.

IPOX® Analyst Lukas Muehlbauer offered commentary to Bloomberg on Etihad Airways' potential IPO, characterizing the airline's improved financial performance and growth plans as a "good turnaround story." Muehlbauer also emphasized the "very positive" sentiment surrounding airline IPOs in emerging markets recently, suggesting a supportive backdrop for Etihad should it pursue a listing.

Amid US-China trade tensions, Chinese tea chain Chagee achieved a $6.2 billion valuation in its Nasdaq debut. Read the Reuters article featuring insights from IPOX® CEO Josef Schuster on the factors contributing to the success of such listings.

IPOX® Analyst Muehlbauer provides expert analysis in Bloomberg on current European IPO trends and why investors are becoming more discerning. He emphasized the growing importance of strong company fundamentals amidst the heightened market volatility.

IPOX® Research Analyst Lukas Muehlbauer was recently quoted by Reuters regarding the impact of market instability on IPOs, specifically commenting on reports that Swedish fintech Klarna has paused its plans for a U.S. listing.

IPOX® Research Analyst Dr. Lukas Muehlbauer was recently interviewed by Reuters about Nvidia-backed CoreWeave's downsized IPO. "The business model doesn't appear fundamentally flawed, but this suggests investors are recalibrating AI infrastructure valuations," noted Muehlbauer as CoreWeave reduced its offering to 37.5 million shares at $40 each, valuing the company at approximately $23 billion—significantly below initial expectations.

IPOX® CEO Josef Schuster was recently interviewed by Reuters regarding eToro's US IPO filing. Schuster noted that companies are seeing a "window of opportunity" to go public and highlighted how eToro's IPO positions the platform to "capture the generational opportunities opening up from the rise of the retail investor globally."

IPOX® CEO Josef Schuster was recently quoted by Reuters on StubHub's IPO filing. The ticketing giant's move to list on the NYSE under "STUB" signals growing confidence in the recovering U.S. IPO market, with Schuster noting it "remains one of the most closely watched IPOs this year and ahead of FIFA 2026."

IPOX® CEO Josef Schuster was recently interviewed by the Financial Times regarding Venture Global's troubling market performance. Following a 36% single-day stock plunge, Schuster provided expert analysis on the LNG producer's IPO struggles.

IPOX® CEO Josef Schuster was interviewed by Bloomberg to discuss Venture Global's aftermarket performance following its recent IPO. Schuster provided insights into the challenging market conditions faced by Venture Global, emphasizing its notably poor stock performance compared to other major energy IPOs in recent decades.

IPOX® CEO Josef Schuster commented in a recent Reuters article, "Karman Holdings valued at nearly $4 billion as shares jump in NYSE debut", offering expert analysis on Karman Holdings' successful IPO and the broader market trends favoring defense and space companies.

IPOX® CEO Josef Schuster was quoted in a recent Reuters article, "Cybersecurity firm SailPoint sets sights on $12.6 billion valuation in US IPO", providing expert insight into SailPoint's IPO and the broader implications for the technology IPO market.

IPOX® Research Analyst Lukas Muehlbauer offered his perspective on the market debut of Maze Therapeutics (MAZE.O), a drug developer focused on chronic kidney diseases. Maze's shares saw a modest 1% increase on its Nasdaq debut, valuing the company at $690.37 million. The company’s debut follows an upsized IPO that raised $140 million.